ライフサイエンスコーパス: progression-free survival

1 gated PLN-induced tumor growth and increased progression-free survival.

2 Primary endpoint was 1-year progression-free survival.

3 pheral T cells was prognostic on overall and progression-free survival.

4 The primary end point was progression-free survival.

5 7 is associated with significantly decreased progression-free survival.

6 The primary endpoint was progression-free survival.

7 toxic effects, objective tumor response, and progression-free survival.

8 Primary end point was investigator assessed progression-free survival.

9 pression in melanoma correlated with shorter progression-free survival.

10 We also assessed progression-free survival.

11 stic value of the IMiD-14 gene signature for progression-free survival.

12 cells inversely correlated with overall and progression-free survival.

13 ligorecurrent prostate cancer (PCa) improves progression-free survival.

14 kinases CDK4 and CDK6 substantially improve progression-free survival.

15 The primary end point was 2-year progression-free survival.

16 ast cancer on the basis of an improvement in progression-free survival.

17 The primary outcome was progression-free-survival.

18 t favorable in terms of (1) hazard ratio for progression-free survival (0.13; 95% credible interval,

19 3.7 weeks [18.1-20.0]; hazard ratio [HR] for progression-free survival 1.28, 95% CI 0.99-1.65, p=0.06

20 ; 95% CI, 0.90-2.08; P = .15), as was median progression-free survival (1.9 vs 2.0 months; HR, 1.61;

21 or in the 75th percentile or higher (median progression-free survival 11.6 months and 16.9 months fo

22 XL2 in the 50th percentile or higher (median progression-free survival 11.7 months and 14.3 months fo

23 here was no significant difference in median progression free survival (12 months vs 9.3 months; P =

24 CI 37.5-54.6] vs 46.4% [37.5-54.8]); median progression-free survival (23.3 weeks [95% CI 19.6-30.4]

25 HR] 0.56 [95% CI 0.34-0.91], p=0.019; median progression-free survival 4.4 months [95% CI 2.1-8.6] vs

26 urvival (OS; 4 years, 30%; 5 years, 28%) and progression-free survival (4 and 5 years, both 13%) appe

27 erapy (HR 0.50 [0.30-0.84], p=0.0084; median progression-free survival 6.3 months [95% CI 2.1-10.4] v

28 mor volume were more likely to have a higher progression-free survival (6.4 vs. 3.74 [P = 0.023] and

29 The primary endpoint was progression-free survival according to an independent re

30 Median progression-free survival according to masked independen

31 The hazard ratio for progression-free survival adjusted by FL International P

32 gnificant association between TIL values and progression-free survival (adjusted HR 0.95, 95% CI 0.90

33 Median progression-free survival after optic nerve infiltration

34 Median progression-free survival after rucaparib treatment was

35 Progression-free survival after the sequence was signifi

36 e primary endpoint was investigator-assessed progression-free survival, analysed by intention-to-trea

37 apse, reduced metastasis, and increased both progression-free survival and 1-year disease-free surviv

38 dian follow-up was 50 months (IQR 41-54) for progression-free survival and 51 months (IQR 46-57) for

39 r estimate were 72% (95% CI, 56% to 84%) for progression-free survival and 79% (95% CI, 63% to 89%) f

40 year rates were 68% (95% CI, 55% to 79%) for progression-free survival and 83% (95% CI, 71% to 91%) f

41 combined with ipilimumab resulted in longer progression-free survival and a higher objective respons

42 (177)Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher res

43 Approval of this drug was based on progression-free survival and interim overall survival d

44 2 year estimates for progression-free survival and ongoing response were 82%

45 or more after 2 wk of CPB, was predictive of progression-free survival and OS.

46 Secondary objectives included progression-free survival and overall response rate, sit

47 d by IWCLL criteria was associated with 100% progression-free survival and overall survival (median 6

48 quantitative parameters were correlated with progression-free survival and overall survival (OS).

49 wed statistically significant differences in progression-free survival and overall survival among res

50 oints for TH3RESA were investigator-assessed progression-free survival and overall survival in the in

51 fter median follow-up of 35.4 months, 2-year progression-free survival and overall survival rates wer

52 The median progression-free survival and overall survival were 12.7

53 Median progression-free survival and overall survival were 3.6

54 Progression-free survival and overall survival were seco

55 alone, with minimal improvement in dysphagia progression-free survival and overall survival with chem

56 tients with advanced NSCLC results in longer progression-free survival and overall survival with pemb

57 ive response rate; secondary end points were progression-free survival and overall survival.

58 methods between the ROC curves (P > 0.4) for progression-free survival and overall survival.

59 Co-primary endpoints were progression-free survival and overall survival; the prim

60 The observed increases in progression-free survival and prostate-specific antigen

61 lenalidomide and dexamethasone would improve progression-free survival and provide better response ra

62 e primary endpoint was investigator-assessed progression-free survival and we report the primary anal

63 nd then correlated to overall survival (OS), progression-free survival, and disease progression rate

64 d in an independent cohort with WHO grading, progression-free survival, and disease-specific survival

65 ansplantation prolonged event-free survival, progression-free survival, and overall survival among pa

66 estimated medians for duration of response, progression-free survival, and overall survival were not

67 nts included toxicity, compliance, response, progression-free survival, and overall survival.

68 assessed associations with overall survival, progression-free survival, and survival after disease pr

69 Median progression-free survival (as assessed by blinded indepe

70 The primary end point was progression-free survival, as assessed by means of blind

71 months (IQR 9.1-28.1), the hazard ratio for progression-free survival assessed by an independent rev

72 The primary endpoint was progression-free survival assessed by an independent rev

73 The primary endpoint was progression-free survival assessed by blinded central re

74 e primary endpoint, reported previously, was progression-free survival assessed by central review; HR

75 The primary endpoint was progression-free survival assessed by masked independent

76 The primary endpoint was progression-free survival, assessed by a masked independ

77 The rate of progression-free survival at 4 years was 83% (95% CI, 73

78 the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% con

79 linded independent review committee assessed progression-free survival, based on all randomly assigne

80 No progression-free survival benefit of AZD8931 compared wi

81 rade were associated with higher ORR, but no progression-free survival benefit.

82 PT-Cy, we found no significant difference in progression-free survival between patients with or witho

83 We noted no difference in progression-free survival between simtuzumab and placebo

84 factors for unfavorable outcome and compare progression-free survival between those treated and not

85 re were no significant differences in 2-year progression-free survival between WBRT and ASCT: 80% (95

86 ced melanoma improves antitumor response and progression-free survival but with a higher frequency of

87 The primary endpoint was progression-free survival by local investigator assessme

88 The primary endpoint was progression-free survival by local investigator assessme

89 The primary end point was progression-free survival by response assessment in neur

90 tic effects of biomarkers were evaluated for progression-free survival by stratified univariate log-r

91 Indeed, deep responses and prolonged progression-free survival can be achieved in relapsed/re

92 Three-year local progression-free survival, cancer-specific survival, and

93 b showed a significant improvement in median progression-free survival compared with chemotherapy (5.

94 rapy is associated with improved overall and progression-free survival compared with conventional rad

95 INTERPRETATION: Binimetinib improved progression-free survival compared with dacarbazine and

96 hase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patie

97 e ipilimumab improves objective response and progression-free survival compared with standard-dose ip

98 e alone only achieves modest improvements in progression-free survival compared with that for chemoth

99 condary end points were time to progression, progression-free survival, conversion to partial hepatec

100 The primary endpoint was progression-free survival defined as the interval betwee

101 , and key secondary endpoints were dysphagia progression-free survival (defined as a worsening of at

102 The primary endpoints were progression-free survival, defined as time to all-cause

103 Overall survival and progression-free survival did not differ among patients

104 0.58, 95% CI 0.36-0.86; p=0.0071), although progression-free survival did not differ between treatme

105 e lymphoma; however, improvements in EFS and progression-free survival did not translate into longer

106 he primary outcome was investigator-assessed progression-free survival evaluated with use of an order

107 nalysis (Aug 1, 2016), 31 patients had had a progression-free survival event (15 with AZD8931 and 16

108 esign methodology triggered by occurrence of progression-free survival events in the placebo group.

109 nd conducted after approximately 120 and 200 progression-free survival events, respectively, occurred

110 tating treatment did not result in prolonged progression-free-survival, fewer toxic effects, or impro

111 nation), in addition to overall survival and progression-free survival from time of randomisation.

112 perienced a partial response (78% shrinkage, progression-free survival > 2.3 years).

113 The primary endpoint of ENDEAVOR, progression-free survival, has been previously reported.

114 umour size (>5 cm) was associated with worse progression-free survival (hazard ratio 2.25, 95% CI 1.3

115 disease, 1.0; 95% CI, 0.6 to 1.6; P = .93), progression-free survival (HR, 1.1; 95% CI, 0.6 to 1.8;

116 Patients with pure dPET(+) had a 3-y progression-free survival identical to patients without

117 Similarly, progression-free survival in both the overall trial popu

118 Median progression-free survival in patients treated with nivol

119 Median progression-free survival in patients with a BRCA-mutant

120 objective was to demonstrate improvement in progression-free survival in patients with COX-2 index >

121 Co-primary endpoints were progression-free survival in patients with EGFR FISH-pos

122 sis groups, rucaparib significantly improved progression-free survival in patients with platinum-sens

123 Median progression-free survival in the intention-to-treat popu

124 The co-primary endpoints were progression-free survival in the intention-to-treat popu

125 Estimated median progression-free survival in the once-a-week arm was 17.

126 val in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohist

127 Two-year OS, progression-free survival, local failure, and distant me

128 isons included 2-year overall survival (OS), progression-free survival, local failure, distant metast

129 in plasma were associated with the shortest progression-free survival (median 2.6 months, 95% CI 1.3

130 While treatment improves progression-free survival, most patients relapse.

131 including a patient with metastatic RCC with progression-free survival of > 3.9 years.

132 l, 27 patients with liposarcoma had a median progression-free survival of 237 days.

133 was 10.5 months (9.4-14.2), with a 12 month progression-free survival of 48% (36-59).

134 2 months (95% CI 10.3-15.5), with a 12 month progression-free survival of 55% (95% CI 45-64).

135 ths (12.7 to not estimable), with a 12 month progression-free survival of 68% (50-81), whereas in the

136 Methylation classes were analysed for progression-free survival outcomes by the Kaplan-Meier m

137 eeks on, 1 week off, based on improvement in progression free survival over placebo (4.8 vs. 0.9 mont

138 regimen in a phase 3 study to show superior progression-free survival over chemotherapy in patients

139 ens with the hope of demonstrating long-term progression-free survival over cyclophosphamide, doxorub

140 RETATION: Dacomitinib significantly improved progression-free survival over gefitinib in first-line t

141 Median overall survival and progression-free survival, overall response rates, and r

142 teria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD

143 rmine whether previous radiotherapy affected progression-free survival, overall survival, and pulmona

144 Progression-free survival, overall survival, and safety

145 ples and investigated their association with progression-free survival, overall survival, clinicopath

146 ortion of patients with an overall response, progression-free survival, overall survival, haematologi

147 were independently associated with inferior progression-free survival (P < .05 for all tests).

148 The coprimary efficacy endpoints were progression-free survival (per independent review commit

149 The 2-year OS, progression free survival (PFS) and local control (LC) i

150 ciations of 25 rSNPs in eight NER genes with progression free survival (PFS) and overall survival (OS

151 ve performance for overall survival (OS) and progression free survival (PFS), with AUC of 0.976 and 0

152 he disease control rate (DCR) at week 6, the progression free-survival (PFS), overall survival (OS),

153 n OR had a significant improvement in median progression-free survival (PFS) (5.1 vs 1.3 months; P =

154 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with flu

155 The primary outcomes were progression-free survival (PFS) and disease-specific mor

156 o) and whether their volumes correlated with progression-free survival (PFS) and overall survival (OS

157 (EFS; 4-year EFS, 31% vs 43%; P < .01), but progression-free survival (PFS) and overall survival (OS

158 monotypic PCs was associated with a shorter progression-free survival (PFS) and overall survival (OS

159 With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS

160 Study endpoints were progression-free survival (PFS) and overall survival (OS

161 etabolic response after 4 cycles, as well as progression-free survival (PFS) and overall survival (OS

162 negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS

163 The primary end point was progression-free survival (PFS) assessed by modified Res

164 better complete response rate (P = .04) and progression-free survival (PFS) at 5 and 10 years (P < .

165 The median progression-free survival (PFS) for all patients was 9.6

166 th the KRAS-variant, cetuximab improved both progression-free survival (PFS) for the first year (HR,

167 -CNG)] monitored on crizotinib could predict progression-free survival (PFS) in a cohort of ALK-rearr

168 moimmunotherapy as a surrogate end point for progression-free survival (PFS) in chronic lymphocytic l

169 F1 methylation and overall survival (OS) and progression-free survival (PFS) in CS patient samples wi

170 To compare progression-free survival (PFS) in patients with LA-SCCH

171 fect sizes between overall survival (OS) and progression-free survival (PFS) in trials of US Food and

172 To date, the median progression-free survival (PFS) is 17.9 months.

173 Progression-free survival (PFS) is the composite of a mo

174 th a complete response rate of 12.5%, median progression-free survival (PFS) of 14 months, and 2-year

175 This trial assessed the progression-free survival (PFS) of bevacizumab or interf

176 between metabolic or clinical endpoints and progression-free survival (PFS) or cause-specific surviv

177 Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS)

178 Overall local tumor progression-free survival (PFS) per nodule (including in

179 d study end point for first-line FL therapy, progression-free survival (PFS) requires extended follow

180 ransplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observ

181 At median follow-up of 15.6 months, progression-free survival (PFS) was 17.4 months and over

182 Progression-free survival (PFS) was calculated as a comp

183 Progression-free survival (PFS) was the primary end poin

184 a in Solid Tumors [RECIST] version 1.1), and progression-free survival (PFS) were determined.

185 mutation status, cytoreductive outcome, and progression-free survival (PFS) were evaluated by using

186 dy demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomi

187 are the effect of metronomic chemotherapy on progression-free survival (PFS) with that of placebo in

188 response rate (ORR) within 6 months, 9-month progression-free survival (PFS), 9-month overall surviva

189 lan-Meier analysis of overall survival (OS), progression-free survival (PFS), actuarial distant metas

190 DEL and DHL were associated with inferior progression-free survival (PFS), and DHL was associated

191 h significantly worse overall survival (OS), progression-free survival (PFS), and distant metastasis-

192 d ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (OR) fo

193 lysis of the kinetics of anti-5T4 responses, progression-free survival (PFS), and overall survival (O

194 ffusion coefficient (ADC) histogram metrics, progression-free survival (PFS), and overall survival.

195 OS, progression-free survival (PFS), and safety were analyze

196 crobial interaction in IPF as they relate to progression-free survival (PFS), fibroblast function, an

197 We described progression-free survival (PFS), overall survival (OS),

198 nt, we examined the durability of remission, progression-free survival (PFS), overall survival (OS),

199 sed to test associations between the CMI and progression-free survival (PFS), overall survival (OS),

200 Progression-free survival (PFS), overall survival (OS),

201 survival (OS), and secondary end points were progression-free survival (PFS), response rate, and toxi

202 The primary end point, progression-free survival (PFS), was evaluated in 183 pa

203 cific estimates of overall survival (OS) and progression-free survival (PFS).

204 Primary end point was progression-free survival (PFS).

205 d genes or signatures linked to response and progression-free survival (PFS).

206 election operator) Cox regression to predict progression-free survival (PFS).

207 e combinations in terms of response rate and progression-free survival (PFS).

208 The primary end point was progression-free survival (PFS).

209 Primary end points were progression-free survival (PFS; overall) and thromboembo

210 ignificantly by stromal TIL value for either progression-free survival (pinteraction=0.23) or overall

211 cal activity (partial response and prolonged progression-free survival) provides an impetus for furth

212 t a median follow-up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-

213 lts The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to

214 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for t

215 weighted values of median overall survival, progression-free survival, response rate, and toxic effe

216 reatment with pembrolizumab conferred longer progression-free survival than did platinum-based therap

217 le-agent brentuximab vedotin and show longer progression-free survival than do patients treated with

218 ion was associated with significantly longer progression-free survival than RVD therapy alone, but ov

219 distinct immune composition correlated with progression-free survival, thereby presenting an in-dept

220 RETATION: The sustained responses and median progression-free survival time, combined with a manageab

221 in the intention-to-treat population (median progression free survival times of 12.6 months and 15.4

222 Median progression-free survival times were 5.7 and 6.7 months

223 Median progression-free survival to date is 22.4 months (95% CI

224 y associated with disease-related mortality, progression-free survival, transplant-related mortality,

225 Despite somewhat prolonged progression-free survival, treatment with lomustine plus

226 ed: two used disease-free survival, one used progression-free survival, two used local failure, and o

227 ng the K-allele showed significantly shorter progression-free survival upon palliative treatment with

228 d a significantly worse overall survival and progression-free survival upon receiving cisplatin after

229 The primary endpoint was progression-free survival using a prespecified one-sided

230 TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutati

231 ant and clinically meaningful improvement in progression-free survival versus chemotherapy in patient

232 termine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.

233 th a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 mont

234 whereas in the T790M-negative group, median progression-free survival was 10.5 months (9.4-14.2), wi

235 Median progression-free survival was 11.1 months (95% CI 8.4-13

236 The median progression-free survival was 11.6 weeks (95% CI, 6.1 to

237 months) in 6 trials with data available, and progression-free survival was 12.4 months (95% CI, 10.0-

238 The overall median progression-free survival was 13.2 months (95% CI 10.3-1

239 Median progression-free survival was 13.3 months (95% CI 9.9-19

240 Median progression-free survival was 13.7 months (95% CI, 9.6-1

241 (95% CI, 16.7 to not estimable), and median progression-free survival was 14.2 months (95% CI, 8.3 t

242 Median hematologic progression-free survival was 14.8 months; 1-year progre

243 In the T790M-positive group, median progression-free survival was 16.0 months (12.7 to not e

244 The median progression-free survival was 17.5 months (95% CI, 8.6-2

245 Median progression-free survival was 2.1 months, and median ove

246 The median progression-free survival was 2.3 years (95% CI, 1.8-2.7

247 Median progression-free survival was 2.7 months (2.1 to 4.2).

248 Locally assessed progression-free survival was 2.7 months longer in the c

249 Median progression-free survival was 2.8 months (95% CI 2.8-3.6

250 an follow-up of 14 months (IQR 7-18), median progression-free survival was 20.8 months (95% CI 16.6-2

251 Median duration of follow-up for progression-free survival was 22.1 months (95% CI 20.3-2

252 atio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 mont

253 Median progression-free survival was 3.48 months (95% CI 1.51-5

254 Median progression-free survival was 3.9 months (interquartile

255 The median progression-free survival was 3.9 months for Ona + Bev v

256 5-year progression-free survival was 36.5% (95% CI 27.8-45.2) o

257 Median dysphagia progression-free survival was 4.1 months (95% CI 3.5-4.8

258 Median progression-free survival was 4.1 months for paclitaxel

259 Median progression-free survival was 4.6 months (95% CI 3.5-5.3

260 After a minimum follow-up of 6 years, median progression-free survival was 43 months and median durat

261 Median ITT progression-free survival was 5.2 months (95% CI, 3.2 to

262 Median progression-free survival was 5.6 months in the ipilimum

263 92 patients with IMiD-14 low scores; 3 year progression-free survival was 52% (95% CI 42-64) for the

264 Estimated median progression-free survival was 6 months (MCL, 14 months;

265 Median progression-free survival was 6.0 (95% CI, 5.0 to 7.3) m

266 he 48 patients with PTEN-low tumours, median progression-free survival was 6.2 months (95% CI 3.6-9.1

267 K pathway-activated patients (n=372), median progression-free survival was 6.8 months (95% CI 4.9-7.1

268 ients with known PI3K status (n=851), median progression-free survival was 6.8 months (95% CI 5.0-7.0

269 Estimated 1 year progression-free survival was 69% (95% CI 60-75), and es

270 At a minimum follow-up of 18 months, median progression-free survival was 8.4 months for patients wh

271 Overall median progression-free survival was 8.5 months.

272 median follow-up of 13.1 months, the median progression-free survival was 8.8 (95% CI, 4.6-15.4) mon

273 Median composite progression-free survival was 9.1 months (95% CI, 4.9 to

274 and one (2%) had distant metastasis; 2-year progression-free survival was 92% (95% CI 77-97).

275 Progression-free survival was also significantly better

276 Progression-free survival was defined as the time from d

277 INTERPRETATION: Progression-free survival was longer in patients who rec

278 e ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients wi

279 Progression-free survival was previously reported to be

280 Progression-free survival was prolonged significantly in

281 s not reported for these 2 studies, although progression-free survival was reported to be between 55%

282 Median progression-free survival was significantly improved in

283 Progression-free survival was significantly longer in th

284 Median progression-free survival was significantly longer in th

285 Progression-free survival was significantly longer in th

286 Median progression-free survival was significantly longer in th

287 signment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with

288 Investigator-assessed median progression-free survival was significantly longer with

289 In the training cohort, progression-free survival was significantly shorter in t

290 The progression-free survival was similar in patients with l

291 The estimated 1-year overall survival and progression-free survival were 40% and 37%, respectively

292 Overall survival (OS) and intracranial progression-free survival were measured from the date of

293 The median time to progression and median progression-free survival were significantly longer in t

294 all survival, disease-specific survival, and progression-free survival were the primary end points.

295 rvival, disease-specific survival (DSS), and progression-free survival were the primary endpoints.

296 ual disease-based algorithm to predict short progression-free survival, which might be incorporated i

297 o a statistically significant improvement in progression-free survival, which, however, did not trans

298 of the previous RADIANT-4 findings of longer progression-free survival with everolimus, our findings

299 Progression-free survival with pembrolizumab was signifi

300 phagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth fact